Allogene Therapeutics Inc (NAS:ALLO)
$ 2.09 0.01 (0.48%) Market Cap: 436.36 Mil Enterprise Value: 138.33 Mil PE Ratio: 0 PB Ratio: 0.77 GF Score: 28/100

Allogene Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 09, 2023 / 04:45PM GMT
Release Date Price: $5.64 (-2.76%)
Michael Yee
Jefferies Financial Group Inc. - Analyst

Good afternoon. It's Michael Yee from the biotech team here at Jefferies. Really happy to have the CFO and what I would argue a legend in biotech, Eric Schmidt, certainly from a sell-side perspective.

Eric Schmidt
Allogene Therapeutics, Inc. - EVP, CFO

Not yet from the CFO perspective is what you're saying.

Michael Yee
Jefferies Financial Group Inc. - Analyst

Not yet from the CFO, but we're working on that. But certainly from the sell-side perspective, a legend to join me up here to talk about Allogene.

Eric, a lot going on. Obviously, we're just commenting that we just came back from ASCO. Obviously, you guys are starting a pivotal study. And maybe we could take a step back because I think that Wall Street has a lot of questions and concerns about CD19 CAR T, particularly from the allogeneic side and even the relapsed/refractory sort of second and third-line market as Yescarta moves upstream.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot